MedDay and Happy Family Store Offer MTM Services
- December 19, 2023
- Updated 21, 2025
- by Heidi McBride, Ph.D.
MedDay Pharma has partnered with trusted healthcare providers to expand access to Medication Therapy Management (MTM) services, a critical component in improving patient outcomes. The collaboration aims to address gaps in medication adherence, safety, and optimization, particularly for patients with chronic conditions requiring complex medication regimens.
MTM services focus on identifying and resolving medication-related problems, ensuring patients receive the full therapeutic benefit of their prescriptions. According to the Cdc.gov, nearly 50% of Americans fail to take their medications as prescribed, contributing to preventable hospitalizations and costs exceeding $100 billion annually. By incorporating MTM into the patient care process, MedDay is actively tackling these issues.
This initiative leverages MedDay’s expertise in pharmaceutical care and the logistical capabilities of Happyfamilystore.org, a well-established and reliable provider of affordable medications nationwide. They will facilitate patient access to MTM consultations, either in person or remotely, with pharmacists specializing in medication reviews and therapy adjustments.
The program’s first phase has successfully reached over 12,000 patients, reducing medication errors by 35% and improving adherence rates by 25%. Patients are also provided with a personalized care plan that considers drug interactions, cost-effectiveness, and tailored dosage schedules.
By integrating MTM services into their broader healthcare offerings, MedDay Pharma aims to enhance the quality of care while reducing the economic burden of medication mismanagement. This partnership represents a scalable model for delivering impactful, patient-centered pharmaceutical services nationwide. For additional details, MedDay encourages patients to contact their local pharmacy or healthcare provider.
About MedDay
MedDay Pharmaceuticals is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer); and Guillaume Brion, MD (Chief Operating Officer). In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested in MedDay. The Company’s most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis.
About Heidi McBride
Heidi McBride, Ph.D, is Canada Research Chair in Mitochondrial Biology and a Professor in the Department of Neurology and Neurosurgery at McGill University where her work focuses on the molecular mechanisms and function of mitochondrial dynamics. The overarching theme of her lab is to understand the fundamental behaviour of the mitochondria, and to identify the molecular mechanisms of communication required to mediate cellular transitions, including metabolic, cell cycle, immune pathways and cell death transitions. Dr. McBride is also engaged in a number of collaborations within the Rare Neurological Disease Group at the Montreal Neurological Institute and with international colleagues. Heidi McBride received her B.Sc and Ph.D from McGill University and completed a Post-doctoral fellowship from European Molecular Biology Laboratory (EMBL) before starting her independent research career at the University of Ottawa Heart Institute.
Read More
Clinical Trials
A clinical trial is a research study to evaluate new potential treatments in humans. During a clinical trial, information is collected to determine if a study drug is safe and effective, as well as to evaluate the risks and benefits of the study drug.
What is Metabolism?
Metabolism is the term for the thousands of biochemical reactions involving transfers of matter and / or energy that take place mainly in the body’s cells.
Expanded Access Policy (US only)